Neisseria meningitidis serogroup B Glycoconjugates
AssigneeChiron Corporation
InventorRobert Seid
Life of this patent
Estimating the term…
Abstract
The present invention pertains generally to Neisseria meningitidis serogroup B glycoconjugates. More particularly, the invention pertains to glycoconjugates formed from a Neisseria meningitidis serogroup B capsular oligosaccharide derivative (MenB OS derivative) in which sialic acid residue N-acetyl groups are replaced with N-acyl groups. The invention also pertains to vaccine formulations containing the glycoconjugates, methods of making the vaccine formulations, and methods of using the vaccine formulations to treat or prevent Neisseria meningitidis serogroup B or E. coli K1 disease in a mammalian subject.
Claims12
A glycoconjugate comprising substantially homogenous sized Neisseria meningitidis serogroup B (MenB) capsular oligosaccharides in which sialic acid residue N-acetyl groups are replaced with saturated N-propionyl groups,
- wherein said MenB oligosaccharides are covalently attached to a protein carrier molecule, have an average degree of polymerization (Dp) of 10 to 20, and further comprise a C3-C16 long-chain aliphatic lipid covalently attached thereto;
- and
- wherein said glycoconjugate has a saccharide-to-protein ratio ranging from 0.10 to 0.25 by weight, and elicits antibodies that do not bind to the human neuroblastoma cell line CHP-134.
A glyconjugate comprising substantially homogenous sized Neisseria meningitidis serogroup B (MenB) capsular oligosaccharides in which sialic acid residue N-acetyl are replaced with saturated N-propionyl groups,
- wherein said MenB oligosaccharides are covalently attached to a CRM197 toxoid protein carrier, have an average Dp of 12 to 18, and further comprise a C3-C16 long-chain aliphatic lipid covalently attached thereto, and
- wherein said glycoconjugate has a saccharide-to-protein ratio ranging from 0.10 to 0.25 by weight, and elicits antibodies that do not bind to the human neuroblastoma cell line CHP-134.
A vaccine composition comprising the combination of:
- a glycoconjugate formed from substantially homogenous sized Neisseria meningitidis serogroup B (MenB) capsular oligosaccharides in which sialic acid residue N-acetyl groups are replaced with saturated N-propionyl groups
- wherein said MenB oligosaccharides are covalently attached to a protein carrier molecule, have an average degree of polymerization (Dp) of 10 to 20, and further comprise a C3-C16 long-chain aliphatic lipid covalently attached thereto, and
- wherein said glycoconjugate has a saccharide-to-protein ratio ranging from 0.10 to 0.25 by weight and, elicits antibodies that do not bind to the human neuroblastoma cell line CHP-134;
- and
- a pharmaceutically acceptable excipient.
A vaccine composition comprising the combination of:
- a glycoconjugate formed from substantially homogenous sized Neisseria meningitidis serogroup B (MenB) capsular oligosaccharides in which sialic acid residue N-acetyl groups are replaced with saturated N-propionyl groups,
- wherein said MenB oligosaccharides are covalently attached to a CRM197 toxoid protein carrier and have an average degree of polymerization (Dp) of 12 to 18, and the MenB OS derivatives further comprise a C3-C16 long-chain aliphatic lipid covalently attached thereto and
- wherein said glycoconjugate has a saccharide-to-protein ratio ranging from 0.10 to 0.25 by weight and, elicits antibodies that do not bind to the human neuroblastoma cell line CHP-134;
- and
- a pharmaceutically acceptable excipient.
Dependencies are inferred from the claim text.